Companion diagnostic testing for targeted cancer therapies: An overview

Genetic Testing and Molecular Biomarkers

Volumn 17, Issue 7, 2013, Pages 515-523

  Fan, Yao Shan ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; B RAF KINASE; BSI 210; CETUXIMAB; CRIZOTINIB; DABRAFENIB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IMATINIB; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; OLAPARIB; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR A; PROTEIN KINASE B; STEM CELL FACTOR; SUNITINIB; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB; VEMURAFENIB;

3' UNTRANSLATED REGION; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RESISTANCE; CELL INVASION; CELL PROLIFERATION; COLORECTAL CANCER; DRUG TREATMENT FAILURE; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL STROMAL TUMOR; GENE DELETION; GENE MUTATION; GENETIC SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MELANOMA; METASTASIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

ANTINEOPLASTIC AGENTS; FEMALE; GENETIC TESTING; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

MAMMALIA;

EID: 84879912933     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2012.0510     Document Type: Review

References (95)

1. Agaram NP, Laquaglia MP, Ustun B, et al. (2008) Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res 14:3204-3215.
2. Allegra CJ, Jessup JM, Somerfield MR, et al. (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091-2096.
3. Amado RG, Wolf M, Peeters M, et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634.
4. AMP (2011) Comments Regarding FDA Draft Guidance for ''In Vitro Companion Diagnostic Devices'' (October, 2011). Available at www.amp.org/publications- resources/position-statements- letters/documents/AMPResponseCompanionDx-Final. pdf
5. Anders CK, Winer EP, Ford JM, et al. (2010) Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clin Cancer Res 16:4702-4710
6. Anderson S, Bloom KJ, Vallera DU, et al. (2012) Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed paraffin-embedded tissue specimens of malignant melanoma. Arch Pathol Lab Med 136:1385-1391.
7. Antonescu CR (2011) The GIST paradigm: lessons for other ki-nase-driven cancers. J Pathol 223:251-261.
8. Antonescu CR, Sommer G, Sarran L, et al. (2003) Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 9:3329-3337.
9. Balak MN, Gong Y, Riely GJ, et al. (2006) Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12:6494-6501.
10. Bang YJ, Van Cutsem E, Feyereislova A, et al. (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687-697.
11. Barber TD, Vogelstein B, Kinzler KW, et al. (2004) Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 351:2883.
12. Bardelli A, Siena S (2010) Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28:1254-1261.
13. Barginear MF, John V, Budman DR (2013) Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. Mol Med 18:1473-1479.
14. Bean J, Riely GJ, Balak M, et al. (2008) Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 14:7519-7525.
15. Bergethon K, Shaw AT, Ou SH, et al. (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863-870.
16. Bokemeyer C, Bondarenko I, Makhson A, et al. (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663-671.
17. Brugger W, Triller N, Blasinska-Morawiec M, et al. (2011) Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 29:4113-4120.
18. Bunn PA Jr., Doebele RC (2011) Genetic testing for lung cancer: reflex versus clinical selection. J Clin Oncol 29:1943-1945.
19. Callahan R, Hurvitz S (2011) Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease. Curr Opin Obstet Gynecol 23:37-43.
20. CAP IASLC and AMP (2011) Lung cancer biomarkers guideline draft recommendations. Available at http://www.cap.org/apps/docs/membership/ transformation/new/lung-public- comment-supporting-materials.pdf
21. Chapman PB, Hauschild A, Robert C, et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516.
22. Chung KY, Shia J, Kemeny NE, et al. (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohis-tochemistry. J Clin Oncol 23:1803-1810.
23. Costa DB, Schumer ST, Tenen DG, et al. (2008) Differential responses to Erlotinib in Epidermal Growth Factor Receptor (EGFR)-mutated lung cancers with acquired resistance to ge-fitinib carrying the L747S or T790M secondary mutations. J Clin Oncol 26:1182-1184.
24. Cunningham D, Starling N, Rao S, et al. (2008) Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36-46.
25. Davies H, Bignell GR, Cox C, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-954.
26. Davies KD, Le AT, Theodoro MF, et al. (2012) Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res 18:4570-4579.
27. Demetri GD, von Mehren M, Blanke CD, et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480.
28. De Roock W, Claes B, Bernasconi D, et al. (2010a) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11:753-762.
29. De Roock W, Jonker DJ, Di Nicolantonio F, et al. (2010b) Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304:1812-1820.
30. Di Nicolantonio F, Martini M, Molinari F, et al. (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705-5712.
31. Drilon A, Rekhtman N, Ladanyi M, et al. (2012) Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol 13:e418-e426.
32. Dutt A, Ramos AH, Hammerman PS, et al. (2011) Inhibitorsensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 6:e20351.
33. FDA (2011) Draft Guidance for Industry and Food and Drug Administration Staff, In Vitro Companion Diagnostic Devices (July 14, 2011). Available at www.fda.gov/MedicalDevices/Device RegulationandGuidance/GuidanceDocuments/ ucm262292.htm
34. Flaherty KT, Puzanov I, Kim KB, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819.
35. Fukuoka M, Wu YL, Thongprasert S, et al. (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29:2866-2874.
36. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, et al., (2007). Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 59:795-805.
37. Gajria D, Chandarlapaty S (2011) HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther 11:263-275.
38. Galanina N, Bossuyt V, Harris LN (2011) Molecular predictors of response to therapy for breast cancer. Cancer J 17:96-103.
39. Goeke F, Franzen A, Menon R, et al. (2012) Rationale for treatment of metastatic squamous cell carcinoma of the lung using FGFR Inhibitors. Chest 142:1020-1026.
40. Guo T, Hajdu M, Agaram NP, et al. (2009) Mechanisms of su-nitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin Cancer Res 15:6862-6870.
41. Hecht JR, Mitchell E, Chidiac T, et al. (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27:672-680.
42. Ho C, Laskin J (2009) EGFR-derived therapies to treat non-small-cell lung cancer. Expert Opin Investig Drugs 18:1133-1145.
43. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048.
44. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765.
45. Katayama R, Khan TM, Benes C, et al. (2011) Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A 108:7535-7540.
46. Keedy VL, Temin S, Somerfield MR, et al. (2011) American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 29:2121-2127.
47. Kobayashi S, Canepa HM, Bailey AS, et al. (2013) Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors. J Thorac Oncol 8:45-51.
48. Koivunen JP, Mermel C, Zejnullahu K, et al. (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14:4275-4283.
49. Kosaka T, Yatabe Y, Endoh H, et al. (2006) Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12:5764-5769.
50. Kwak EL, Bang YJ, Camidge DR, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703.
51. Lasota J, Dansonka-Mieszkowska A, Sobin LH, et al. (2004) A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest 84:874-883.
52. Liao X, Lochhead P, Nishihara R, et al. (2012) Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 367:1596-1606.
53. Lièvre A, Bachet JB, Boige V, et al. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colo-rectal cancer treated with cetuximab. J Clin Oncol 26:374-379.
54. Lin JS, Webber EM, Senger CA, et al. (2011) Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer. Am J Cancer Res 1:650-662.
55. Loupakis F, Ruzzo A, Cremolini C, et al. (2009) KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic co-lorectal cancer. Br J Cancer 101:715-721.
56. Maemondo M, Inoue A, Kobayashi K, et al. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388.
57. Maheswaran S, Sequist LV, Nagrath S, et al. (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359:366-377.
58. Maleddu A, Pantaleo MA, Nannini M, et al. (2009) Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review). Oncol Rep 21:1359-1366.
59. Mitsudomi T, Morita S, Yatabe Y, et al. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121-128.
60. Mok TS, Wu YL, Thongprasert S, et al. (2009) Gefitinib or car-boplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957.
61. Moroni M, Veronese S, Benvenuti S, et al. (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6:279-286.
62. Nahta R (2012) Molecular mechanisms of trastuzumab-based treatment in HER2-overexpressing breast cancer. ISRN Oncol 2012:428062.
63. Nazarian R, Shi H, Wang Q, et al. (2010) Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-977.
64. Paik PK, Arcila ME, Fara M, et al. (2011) Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 29:2046-2051.
65. Pao W, Girard N (2011) New driver mutations in non-small-cell lung cancer. Lancet Oncol 12:175-180.
66. Park YS, Hwang HS, Park HJ, et al. (2012). Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? Hum Pathol 43:413-422.
67. Ribas A, Flaherty KT (2011) BRAF targeted therapy changes the treatmentparadigminmelanoma.Nat Rev Clin Oncol8:426-433.
68. Riely GJ, Marks J, Pao W (2009) KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 6:201-205.
69. Rikova K, Guo A, Zeng Q, et al. (2007) Global survey of phos-photyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190-1203.
70. Rimkunas VM, Crosby KE, Li D, et al. (2012) Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res 18:4449-4457.
71. Rosell R, Moran T, Queralt C, et al. (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958-967.
72. Ross JS, Slodkowska EA, Symmans WF, et al. (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14:320-368.
73. Saltz LB, Meropol NJ, Loehrer PJ Sr., et al. (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208.
74. Sasaki H, Shitara M, Yokota K, et al. (2012) Increased FGFR1 copy number in lung squamous cell carcinomas. Mol Med Report 5:725-728.
75. Schildhaus HU, Heukamp LC, Merkelbach-Bruse S, et al. (2012) Definition of a fluorescence in-situ hybridization score identifies high-and low-level FGFR1 amplification types in squa-mous cell lung cancer. Mod Pathol 25:1473-1480.
76. Sendur MA, Aksoy S, Altundag K (2012) Pertuzumab in HER2-positive breast cancer. Curr Med Res Opin 28:1709-1716.
77. Smalley KSM (2010) Understanding melanoma signaling networks as the basis for molecular targeted therapy. J Invest Dermatol 130:28-37.
78. Snozek CL, O'Kane DJ, Algeciras-Schimnich A (2009) Pharmacoge-netics of solid tumors: directed therapy in breast, lung, and colo-rectal cancer: a paper from the 2008 william beaumont hospital symposium on molecular pathology. J Mol Diagn 11:381-389.
79. Soda M, Choi YL, Enomoto M, et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566.
80. Sosman JA, Kim KB, Schuchter L, et al. (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707-714.
81. Su F, Viros A, Milagre C, et al. (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366:207-215.
82. Takeuchi K, Soda M, Togashi Y, et al. (2012) RET, ROS1 and ALK fusions in lung cancer. Nat Med 18:378-381.
83. Takezawa K, Okamoto I, Nishio K, et al. (2011) Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer. Clin Cancer Res 17:2140-2148.
84. Tol J, Dijkstra JR, Klomp M, et al. (2010) Markers for EGFR pathway activation as predictor of outcome in metastatic co-lorectal cancer patients treated with or without cetuximab. Eur J Cancer 46:1997-2009.
85. Tol J, Koopman M, Cats A, et al. (2009) Chemotherapy, bev-acizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:563-572.
86. Turner SD, Yeung D, Hadfield K, et al. (2007) Cook SJ, Alexander DR. The NPM-ALK tyrosine kinase mimics TCR signalling pathways, inducing NFAT and AP-1 by RAS-dependent mechanisms. Cell Signal 19:740-747.
87. Vakiani E, Solit DB (2011) KRAS and BRAF: drug targets and predictive biomarkers. J Pathol 223:219-229.
88. Vaughn CP, Zobell SD, Furtado LV, et al. (2011) Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 50:307-312.
89. Wainberg ZA, Anghel A, Desai AJ, et al. (2010) Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 16:1509-1519.
90. Wardelmann E, Losen I, Hans V, et al. (2003) Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit pro-tooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 106:887-895.
91. Weiss J, Sos ML, Seidel D, et al. (2010) Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2:62ra93.
92. Wolff AC, Hammond ME, Schwartz JN, et al. (2007) American Society of Clinical Oncology/College of American Patholo-gists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18-43.
93. Wu JY, Wu SG, Yang CH, et al. (2008) Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 14:4877-4882.
94. Wu JY, Yu CJ, Chang YC, et al. (2011) Effectiveness of tyrosine kinase inhibitors on ''uncommon'' epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 17:3812-3821.
95. Zhang J, Zhang L, Su X, et al. (2012) Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin Cancer Res 18:6658-6667.